RNS Number : 4618Q Renalytix PLC 17 December 2024 TR-1: Standard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Renalytix PLC GB00BYWL4Y04 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An event changing the

RNS Number : 7163P Renalytix PLC 11 December 2024 Renalytix plc ("Renalytix" or the "Company") Director/PDMR dealings LONDON and NEW YORK, 11 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the following Director dealings. On 5 December, certain investment vehicles connected with Christopher Mills, Non-Executive Chairman, sold 48,601

RNS Number : 4015P Renalytix PLC 09 December 2024 Renalytix plc ("Renalytix" or the "Company") Director/PDMR share purchase LONDON and NEW YORK, 9 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that today Howard Doran, President of Renalytix, bought 50,000 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price

RNS Number : 0504P Renalytix PLC 06 December 2024 Renalytix plc ("Renalytix" or the "Company") Director/PDMR share purchase LONDON and NEW YORK, 6 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that yesterday James McCullough, Chief Executive Officer, bought 53,300 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company

RNS Number : 8190O Renalytix PLC 04 December 2024 Renalytix plc ("Renalytix" or the "Company") Director/PDMR share purchase LONDON and NEW YORK, 4 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that today Julian Baines, Executive Chairman, bought 23,989 ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price

RNS Number : 3698O Renalytix PLC 02 December 2024 Renalytix plc ("Renalytix" or the "Company") Directorate Change Robert Naylor appointed as Non-Executive Director LONDON and NEW YORK, 2 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Robert Naylor as Non-Executive Director with immediate effect. Robert has 29 years'

RNS Number : 7324N Renalytix PLC 26 November 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Renalytix PLC GB00BYWL4Y04 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An

RNS Number : 5871N Renalytix PLC 26 November 2024 Renalytix plc ("Renalytix" or the "Company") Publication of Annual Report 2024 and Notice of 2024 Annual General Meeting LONDON and NEW YORK, 26 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Annual Report for the year ended 30 June 2024 and the Notice of 2024 Annual General

RNS Number : 5838N Renalytix PLC 25 November 2024 TR-1: Standard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Renalytix PLC GB00BYWL4Y04 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An event changing the

RNS Number : 0459N Renalytix PLC 21 November 2024 Renalytix plc ("Renalytix" or the "Company") Audited Full Year Fiscal 2024 Results LONDON and NEW YORK, 21 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and health care cost reduction, reports audited financial results for the fiscal year ended 30 June 2024. The Company has now largely completed its reorganization from

RNS Number : 9436M Renalytix PLC 20 November 2024 Renalytix plc ("Renalytix" or the "Company") Financial Results for First Quarter of Fiscal Year 2025 LONDON and NEW YORK, 20 November, 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal quarter of 2025 ended September 30, 2024. First Quarter Fiscal 2025 and

RNS Number : 5262L Renalytix PLC 08 November 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Renalytix plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An

RNS Number : 4228L Renalytix PLC 07 November 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Renalytix plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An

RNS Number : 4073L Renalytix PLC 07 November 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name Harwood Capital LLP City of registered office (if applicable) Country of registered office (if applicable) Name City of registered office Country of registered office Harwood Capital LLP London United Kingdom Harwood

RNS Number : 2208L Renalytix PLC 06 November 2024 Renalytix plc ("Renalytix" or the "Company") Cancellation of Ordinary Shares Total Voting Rights LONDON and NEW YORK, 6 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, following the Placing and Subscription undertaken by the Company which was announced on 30 September 2024 (the

RNS Number : 8981K Renalytix PLC 05 November 2024 Renalytix plc ("Renalytix" or the "Company") Directorate Change Julian Baines MBE appointed as Executive Chairman LONDON and NEW YORK, 5 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Julian Baines MBE as Executive Chairman after shareholders approved the resolution

RNS Number : 8983K Renalytix PLC 05 November 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Ruffer LLP City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the

RNS Number : 8880K Renalytix PLC 04 November 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of financial instruments; An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name Pentwater Capital Management LP City of registered office (if applicable) Country of registered office (if applicable) US 4. Details of the shareholder Full name of

RNS Number : 4687K Renalytix PLC 31 October 2024 Renalytix plc ("Renalytix" or the "Company") Directorate Change LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dan Levangie, Non-Executive Director has stepped down from the Board of Renalytix, effective immediately, following the General Meeting today.

RNS Number : 4622K Renalytix PLC 31 October 2024 Renalytix plc ("Renalytix" or the "Company") Result of General Meeting LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, at the General Meeting ("GM") held earlier today, all resolutions were passed. Further details of each of the resolutions are set out in the

RNS Number : 2208L Renalytix PLC 06 November 2024 Renalytix plc ("Renalytix" or the "Company") Cancellation of Ordinary Shares Total Voting Rights LONDON and NEW YORK, 6 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, following the Placing and Subscription undertaken by the Company which was announced on 30 September 2024 (the

RNS Number : 8981K Renalytix PLC 05 November 2024 Renalytix plc ("Renalytix" or the "Company") Directorate Change Julian Baines MBE appointed as Executive Chairman LONDON and NEW YORK, 5 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Julian Baines MBE as Executive Chairman after shareholders approved the resolution

RNS Number : 8983K Renalytix PLC 05 November 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name Ruffer LLP City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the

RNS Number : 8880K Renalytix PLC 04 November 2024 TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of financial instruments; An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name Pentwater Capital Management LP City of registered office (if applicable) Country of registered office (if applicable) US 4. Details of the shareholder Full name of

RNS Number : 4687K Renalytix PLC 31 October 2024 Renalytix plc ("Renalytix" or the "Company") Directorate Change LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that Dan Levangie, Non-Executive Director has stepped down from the Board of Renalytix, effective immediately, following the General Meeting today.

RNS Number : 4622K Renalytix PLC 31 October 2024 Renalytix plc ("Renalytix" or the "Company") Result of General Meeting LONDON and NEW YORK, 31 October 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, at the General Meeting ("GM") held earlier today, all resolutions were passed. Further details of each of the resolutions are set out in the

RNS Number : 9446H Renalytix PLC 11 October 2024   Renalytix plc (" Renalytix " or the " Company ")   Posting of Circular and Notice of General Meeting   LONDON and NEW YORK , 11 October, 2024   ̶   Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics

RNS Number : 7887H Renalytix PLC 11 October 2024     Renalytix plc ("Renalytix" or the "Company")   Director/PDMR Dealing   LONDON and NEW YORK , 11 October 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing

RNS Number : 7886H Renalytix PLC 11 October 2024   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non- UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3.

RNS Number : 7884H Renalytix PLC 11 October 2024   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BYWL4Y04 Issuer Name RENALYTIX PLC UK or Non- UK Issuer UK 2. Reason for Notification An event changing the breakdown of voting rights 3.

RNS Number : 5976H Renalytix PLC 09 October 2024   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing

RNS Number : 4004H Renalytix PLC 08 October 2024   Renalytix plc (" Renalytix " or the " Company ")   Admission of Shares & Total Voting Rights   Renalytix (AIM: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to

RNS Number : 3346H Renalytix PLC 08 October 2024     Renalytix plc ("Renalytix" or the "Company")   Commencement of trading on OTCQB in the United States   Renalytix plc American Depository Shares (ADSs) begin trading on   OTCQB Venture Market under symbol "RNLXY" effective from Market Open on

RNS Number : 4887G Renalytix PLC 01 October 2024   THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE

RNS Number : 4130G Renalytix PLC 01 October 2024     Renalytix plc ("Renalytix" or the "Company")   Audited US GAAP financial results for the fiscal year ended 30 June 2024   LONDON and NEW YORK , 1 October, 2024   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in

RNS Number : 3313G Renalytix PLC 30 September 2024   THIS ANNOUNCEMENT, INCLUDING THE APPENDICES TO THIS ANNOUNCEMENT, AND THE INFORMATION CONTAINED HEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES ,